Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript Summary
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript Summary
Non-GAAP recurring EBITDA for Q3 2024 was a net loss of $9.2 million, worsening from a loss of $6.2 million in Q3 2023.The following is a summary of the Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript:
以下是jaguar health公司（JAGX）2024年第三季度業績會的摘要：
Financial Performance:
財務表現：
Jaguar Health reported Q3 2024 revenue of approximately $3.1 million, a 14% increase from Q2 2024 and an 11% increase from Q3 2023.
Net loss from operations decreased by $1.5 million compared to the previous year from $8.8 million in Q3 2023 to $7.3 million in Q3 2024.
Non-GAAP recurring EBITDA for Q3 2024 was a net loss of $9.2 million, worsening from a loss of $6.2 million in Q3 2023.
jaguar health報告2024年第三季度的營業收入約爲310萬，較2024年第二季度增長14%，較2023年第三季度增長11%。
與去年相比，運營淨虧損減少了150萬，從2023年第三季度的880萬降至2024年第三季度的730萬。
2024年第三季度的非公認會計原則（Non-GAAP）經常性EBITDA淨虧損爲920萬，較2023年第三季度的620萬虧損惡化。
Business Progress:
業務進展：
Launched FDA-approved oral mucositis prescription product, Gelclair, expanding Jaguar's commercialized products.
Achieved significant milestones in clinical development, particularly with the OnTarget Phase III trial in breast and lung cancer patients.
Continued progress with crofelemer for rare diseases, focusing on two Phase II trials for congenital diarrheal disorders and short bowel syndrome with intestinal failure.
推出了FDA批准的口服黏膜炎處方產品Gelclair，擴展了jaguar的商業化產品。
在臨床開發中取得了重大里程碑，特別是在針對乳腺癌和肺癌患者的OnTarget第三階段試驗中。
對於罕見疾病，繼續推進crofelemer的研究，重點是針對先天性腹瀉障礙和腸功能不全的短腸綜合徵的兩項二期臨床試驗。
Opportunities:
機會：
Entered the supportive care market for cancer treatment side effects with new products like Gelclair for oral mucositis, addressing significant unmet medical needs.
Potential revenue growth through clinical trials in Europe and the MENA regions for microvillus inclusion disease and short bowel syndrome.
進入癌症治療副作用的支持性護理市場，推出了新產品如Gelclair用於口腔黏膜炎，解決了重大的醫療未滿足需求。
通過在歐洲和中東及北非地區進行微絨毛包涵病和短腸綜合徵的臨床試驗，可能實現營業收入增長。
Risks:
風險：
Financial performance shows increasing losses year-over-year, highlighting challenges in reaching profitability.
Clinical trials, particularly for cancer therapy-related diarrhea, face uncertainties in achieving primary endpoints, which may impact regulatory approval and market acceptance.
財務表現顯示逐年虧損增加，突顯出實現盈利的挑戰。
臨床試驗，特別是針對癌症治療相關腹瀉的試驗，面臨達到主要終點的不確定性，這可能影響監管審批和市場接受度。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
